<DOC>
	<DOC>NCT02735083</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety and efficacy of UCART 19 administration to patients with advanced lymphoid malignancies.</brief_summary>
	<brief_title>A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Malignancies Who Have Been Previously Administered With UCART19</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Written informed consent obtained prior any studyspecific procedure (patient or parent(s) or legal representative) and before enrolment into the parent study or compassionate use program; Patient dosed with UCART19 who completed or discontinued early from a sponsored or from any investigatorinitiated study that tested UCART19, or patients who were administered UCART19 under a special access scheme (compassionate use); Female patients of childbearing potential and male patients with partners of childbearing potential must continue to use an effective method of birth control as well as their partners. No exclusion criteria for this study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>